Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults

被引:279
作者
Martin, R
Kuzniecky, R
Ho, S
Hetherington, H
Pan, J
Sinclair, K
Gilliam, F
Faught, E
机构
[1] Univ Alabama, Dept Neurol, UAB Epilepsy Ctr, Birmingham, AL 35294 USA
[2] Univ Alabama, Ctr Nucl Imaging Res, Birmingham, AL USA
关键词
D O I
10.1212/WNL.52.2.321
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To study the acute and steady-state cognitive effects of three new antiepileptic drugs (AEDs): gabapentin, lamotrigine, and topiramate. Background: Several newer antiepileptic medications approved recently by the Food and Drug Administration are gaining attention as efficacious alternatives to established AEDs. Greater tolerability with fewer side effects are reported in some. However, the potential cognitive effects of these newer AEDs have received limited attention. Methods: Healthy young adults randomized to either of the three drugs were administered tests of attention, psychomotor speed, language, memory, and mood at baseline (predrug), acute single-dose period, and after 2 and 4 weeks on the drug. Results: Compared with baseline, the topiramate group had selective, statistically significant declines on measures of attention and word fluency at acute doses, whereas the other two AED groups had no performance changes. At the 2- and 4-week test periods, only the topiramate subjects continued to display neurocognitive effects from drug administration. Conclusions: Results demonstrate potential acute and steady-state adverse cognitive effects for topiramate, whereas minimal effects were displayed for either gabapentin or lamotrigine in young healthy adults.
引用
收藏
页码:321 / 327
页数:7
相关论文
共 38 条
[1]  
BENMENACHEM E, 1996, EPILEPSIA, V37, P763
[2]  
Benton A. L., 1983, MULTILINGUAL APHASIA, DOI [DOI 10.1037/T10132-000, 10.1037/t10132-000]
[3]   Gabapentin monotherapy .2. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures [J].
Beydoun, A ;
Fischer, J ;
Labar, DR ;
Harden, C ;
Cantrell, D ;
Uthman, BM ;
Sackellares, JC ;
AbouKhalil, B ;
Ramsay, RE ;
Hayes, A ;
Greiner, M ;
Garofalo, E ;
Pierce, M .
NEUROLOGY, 1997, 49 (03) :746-752
[4]   DOUBLE-BLIND COMPARISON OF LAMOTRIGINE AND CARBAMAZEPINE IN NEWLY-DIAGNOSED EPILEPSY [J].
BRODIE, MJ ;
RICHENS, A ;
YUEN, AWC .
LANCET, 1995, 345 (8948) :476-479
[5]   EVALUATING STORAGE, RETENTION, AND RETRIEVAL IN DISORDERED MEMORY AND LEARNING [J].
BUSCHKE, H ;
FULD, PA .
NEUROLOGY, 1974, 24 (11) :1019-1025
[6]   NEUROPSYCHOLOGICAL ABILITIES BEFORE AND AFTER 5 YEARS OF STABLE ANTIEPILEPTIC DRUG-THERAPY [J].
DODRILL, CB ;
WILENSKY, AJ .
EPILEPSIA, 1992, 33 (02) :327-334
[7]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages [J].
Faught, E ;
Wilder, BJ ;
Ramsay, RE ;
Reife, RA ;
Kramer, LD ;
Pledger, GW ;
Karim, RM ;
Barr, A ;
Fischer, J ;
Bergen, D ;
Boor, D ;
Browne, T ;
Davenport, J ;
Dichter, M ;
Drake, M ;
Kuzniecky, R ;
Mamdani, M ;
McCutchen, C ;
Naritoku, D ;
Potolicchio, S ;
Ramani, V ;
Ramsay, R ;
Shinnar, S ;
So, E ;
Wilder, B .
NEUROLOGY, 1996, 46 (06) :1684-1690
[8]  
Faught Edward, 1997, Neurology, V48, pA336
[9]  
Faught Edward, 1997, Epilepsia, V38, P97
[10]   LAMOTRIGINE - AN UPDATE OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN EPILEPSY [J].
FITTON, A ;
GOA, KL .
DRUGS, 1995, 50 (04) :691-713